The dual SGLT1/2 inhibitor sotagliflozin reduced CV mortality and HHF in patients with HF, both in HFrEF as well as HFpEF, prevented the development of HF in patients with T2D and CKD in the SCORED [22], and SOLOIST [32] trials, similar to the benefits by other SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is chronic kidney disease.